On-Q-ity

On-Q-ity is a biotechnology startup founded in 2004 and is dedicated to providing physicians with advanced tools to improve cancer treatment decisions and enhance patient outcomes. The company's slogan "Empowering physicians with advanced tools to improve cancer treatment decisions and enhance patient outcomes" reflects its mission to optimize cancer treatment decisions for individual patients. On-Q-ity's platform leverages DNA repair biomarkers for predicting treatment response and microfluidic chip technology for capturing, enumerating, and characterizing circulating tumor cells (CTCs) in the bloodstream. The last investment in On-Q-ity was a $5.00M Series B round led by Atlas Venture, Mohr Davidow Ventures, and Physic Ventures on 28 February 2012. This investment signifies the confidence of established venture capital firms in On-Q-ity's potential to make a significant impact in the biotechnology industry. With a focus on improving decision-making across various cancers and ultimately improving patient quality of life and survival rates, On-Q-ity is likely to attract further attention and investment in the future.